Novartis Licenses Drug Candidate From Abogen for Up to $7.8 Billion
Swiss drugmaker Novartis has struck a deal valued at up to $7.8 billion to license a drug candidate from China's Abogen Biosciences, including an upfront payment of $575 million and options over future therapies. This partnership represents the latest collaboration between a major Western pharmaceutical company and a Chinese biotech firm.
8 billion to license a drug candidate from China’s Abogen Biosciences and secure options on future therapies, in the latest tie-up between a major Western drugmaker and a Chinese biotech upstart. The Swiss company is paying $575 million upfront and co…